Pages that link to "Q68130766"
Jump to navigation
Jump to search
The following pages link to Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not (Q68130766):
Displaying 50 items.
- Pharmacological interventions for preventing recurrent urinary stones in adults and children (Q24194727) (← links)
- Pharmacological interventions for preventing recurrent urinary stones in adults and children (Q24202533) (← links)
- Pharmacological interventions for preventing complications in idiopathic hypercalciuria (Q24241657) (← links)
- Kidney stone disease (Q24536113) (← links)
- Evaluation and medical management of the kidney stone patient (Q24630579) (← links)
- The elementome of calcium-based urinary stones and its role in urolithiasis (Q26786250) (← links)
- Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis (Q28254324) (← links)
- Evaluating the effectiveness of adding magnesium chloride to conventional protocol of citrate alkali therapy on kidney stone size. (Q30367714) (← links)
- A case of a lower pole renal calculus managed with percutaneous nephrolithotomy (Q33330257) (← links)
- Effects of hydrochlorothiazide on kidney stone therapy with extracorporeal shock wave lithotripsy (Q34024363) (← links)
- Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management (Q34265048) (← links)
- X-linked recessive nephrolithiasis: Presentation and diagnosis in children (Q34469458) (← links)
- Kidney stones: pathophysiology and medical management. (Q34489092) (← links)
- Caffeine intake and the risk of kidney stones (Q34511332) (← links)
- Thiazide diuretic prophylaxis for kidney stones and the risk of diabetes mellitus. (Q34615244) (← links)
- Bioavailability of magnesium from different pharmaceutical formulations (Q34623716) (← links)
- Pharmacotherapy of urolithiasis: evidence from clinical trials (Q34936200) (← links)
- Pharmacology of stone disease (Q34936294) (← links)
- Nephrolithiasis-associated bone disease: pathogenesis and treatment options (Q34936324) (← links)
- Hyperuricosuric calcium nephrolithiasis (Q35021705) (← links)
- Medical treatment of nephrolithiasis. (Q35021730) (← links)
- Clinical practice. Calcium kidney stones (Q35335724) (← links)
- Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? (Q35587935) (← links)
- Metaphylaxis, diet and lifestyle in stone disease (Q35643131) (← links)
- Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline (Q36325704) (← links)
- Idiopathic hypercalciuria (Q36413105) (← links)
- Evaluating the effectiveness of adding magnesium chloride to conventional protocol of citrate alkali therapy in children with urolithiasis (Q36422649) (← links)
- Annual Incidence of Nephrolithiasis among Children and Adults in South Carolina from 1997 to 2012. (Q36687003) (← links)
- Epidemiology of stone disease (Q36902334) (← links)
- Pathophysiology and management of calcium stones (Q36902344) (← links)
- Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health (Q37070036) (← links)
- Activation of the Ca(2 )-sensing receptor increases renal claudin-14 expression and urinary Ca(2 ) excretion. (Q37123850) (← links)
- Kidney stones: an update on current pharmacological management and future directions (Q37169623) (← links)
- Thiosulfate reduces calcium phosphate nephrolithiasis (Q37211104) (← links)
- Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement (Q37366264) (← links)
- Evidence for durable kidney stone prevention over several decades (Q37401624) (← links)
- Lowering urinary oxalate excretion to decrease calcium oxalate stone disease (Q37422038) (← links)
- Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria (Q37476617) (← links)
- Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation (Q37582208) (← links)
- CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update (Q37585262) (← links)
- Effect of Cystone® on urinary composition and stone formation over a one year period (Q37586831) (← links)
- The Evidence-Based Use of Thiazide Diuretics in Hypertension and Nephrolithiasis (Q37783495) (← links)
- An Update on the Changing Epidemiology and Metabolic Risk Factors in Pediatric Kidney Stone Disease (Q37898931) (← links)
- Urolithiasis in the Emergency Department (Q37904062) (← links)
- Pathophysiology-Based Treatment of Idiopathic Calcium Kidney Stones (Q37913747) (← links)
- The impact of metaphylaxis of kidney stone disease in the renal function at long term in active kidney stone formers patients (Q37920747) (← links)
- Diuretics and Disorders of Calcium Homeostasis (Q37958276) (← links)
- Diuretic-Associated Hyponatremia (Q37958279) (← links)
- Prophylaxis in idiopathic calcium urolithiasis (Q38036645) (← links)
- Abnormalities of 24-hour urine composition in first-time and recurrent stone-formers (Q38037888) (← links)